Resumen

ALMAGRO VAZQUEZ, Delfina. Acquired hemophilia A. Rev Cubana Hematol Inmunol Hemoter [online]. 2010, vol.26, n.3, pp. 174-185. ISSN 1561-2996.

Acquired hemophilia A (AHA) is an uncommon hemorrhagic disorder characterized by presence of autoantibodies to circulating factor VIII. Approximately in half of cases it is noted a heterogeneous group of pathological processes including among others, autoimmune and malignant diseases and during pregnancy, labor and puerperium. Hemorrhagic manifestations are variable and mainly of mucous cutaneous type. Diagnosis is based on the finding of a patient presenting with hemorrhagic manifestations, extension of activated partial thromboplastin time (APTT), decrease of Factor VIII activity, and presence of Factor VIII inhibitors. AHA treatment includes the control of hemorrhagic manifestations and the suppression of antibody production. The recombinant factor VIIIa (rVIIIaF) concentration and the prothrombin-complex concentrations (PCC) are considered like the first-line antihemorrhagic treatment. As alternative therapy in some cases the FCIII concentration, the plasmapheresis and extracorporeal immuno-adsorption may be used. The prednisone alone or associated with cyclophosphamide is the firs-line immunosuppressive treatment. In refractory patients it may be administered as a second-line therapy, the Rituximab (anti-CD20). With the use of Azathioprine, Cyclosporine, Vincristine and the Mycophenolate mofetil variable results have been achieved.

Palabras clave : Acquired hemophilia A; autoantibodies to factor VIII; corticosteroids; Cyclophosphamide; Rituximab.

        · resumen en Español     · texto en Español     · Español ( pdf )